Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.NEUCOM.2020.05.078 | ||||
| Año | 2020 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Artificial intelligence and all its supporting tools, e.g. machine and deep learning in computational intelligence-based systems, are rebuilding our society (economy, education, life-style, etc.) and promising a new era for the social welfare state. In this paper we summarize recent advances in data science and artificial intelligence within the interplay between natural and artificial computation. A review of recent works published in the latter field and the state the art are summarized in a comprehensive and self-contained way to provide a baseline framework for the international community in artificial intelligence. Moreover, this paper aims to provide a complete analysis and some relevant discussions of the current trends and insights within several theoretical and application fields covered in the essay, from theoretical models in artificial intelligence and machine learning to the most prospective applications in robotics, neuroscience, brain computer interfaces, medicine and society, in general.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Górriz, Juan M. | Hombre |
Universidad de Granada - España
University of Cambridge - Reino Unido UNIV GRANADA - España UNIV CAMBRIDGE - Reino Unido |
| 2 | Ramírez, Javier | Hombre |
Universidad de Granada - España
UNIV GRANADA - España |
| 3 | Ortíz, Andrés | Hombre |
Universidad de Málaga - España
Univ Malaga - España |
| 4 | Martínez-Murcia, Francisco J. | Hombre |
Universidad de Málaga - España
Univ Malaga - España |
| 5 | Segovia, Fermin | - |
Universidad de Granada - España
UNIV GRANADA - España |
| 6 | Suckling, John | Hombre |
University of Cambridge - Reino Unido
UNIV CAMBRIDGE - Reino Unido |
| 7 | Leming, Matthew | Hombre |
University of Cambridge - Reino Unido
UNIV CAMBRIDGE - Reino Unido |
| 8 | Zhang, Yu Dong | - |
University of Leicester - Reino Unido
Univ Leicester - Reino Unido |
| 9 | Ramon Alvarez-Sanchez, Jose | Hombre |
Univ Nacl Educ Distancia - España
Universidad Nacional de Educación a Distancia - España |
| 9 | Álvarez-Sánchez, Jose Ramón | Hombre |
Universidad Nacional de Educación a Distancia - España
|
| 10 | Bologna, Guido | Hombre |
Université de Genève - Suiza
Univ Geneva - Suiza |
| 11 | Bonomini, Paula | Mujer |
Universidad de Buenos Aires - Argentina
UNIV BUENOS AIRES - Argentina |
| 12 | Casado, Fernando E. | Hombre |
Universidad de Santiago de Compostela - España
Univ Santiago de Compostela - España |
| 13 | Charte, David | Hombre |
Universidad de Jaén - España
Univ Jaen - España |
| 14 | Charte, Francisco | Hombre |
Universidad de Jaén - España
Univ Jaen - España |
| 15 | CONTRERAS-ARRIAGADA, RICARDO | Hombre |
Universidad de Concepción - Chile
|
| 16 | Cuesta-Infante, Alfredo | Hombre |
Universidad Rey Juan Carlos - España
Univ Rey Juan Carlos - España |
| 17 | Duro, Richard J. | Hombre |
Universidade da Coruña - España
Univ A Coruna - España |
| 18 | Fernández-Caballero, A. | Hombre |
Universidad de Castilla-La Mancha - España
Univ Castilla La Mancha - España |
| 19 | Fernández-Jover, Eduardo | Hombre |
Universidad Miguel Hernández de Elche - España
Univ Miguel Hernandez - España |
| 20 | Gómez-Vilda, Pedro | Hombre |
Universidad Politécnica de Madrid - España
Univ Politecn Madrid - España |
| 21 | Grana, Manuel | Hombre |
Universidad del País Vasco - España
Univ Basque Country - España |
| 22 | Herrera, Francisco | Hombre |
Universidad de Granada - España
UNIV GRANADA - España |
| 23 | Iglesias, Roberto | Hombre |
Universidad de Santiago de Compostela - España
Univ Santiago de Compostela - España |
| 24 | Lekova, Anna | Mujer |
Bulgarian Academy of Sciences - Bulgaria
Bulgarian Acad Sci - Bulgaria The Bulgarian Academy of Sciences - Bulgaria |
| 25 | de Lope, J. | Hombre |
Universidad Politécnica de Madrid - España
Univ Politecn Madrid - España |
| 26 | López-Rubio, Ezequiel | Hombre |
Universidad de Málaga - España
Univ Malaga - España |
| 27 | Martínez-Tomás, Rafael | Hombre |
Universidad Nacional de Educación a Distancia - España
Univ Nacl Educ Distancia - España |
| 28 | Molina-Cabello, Miguel A. | Hombre |
Universidad de Málaga - España
Univ Malaga - España |
| 29 | Montemayor, Antonio S. | Hombre |
Universidad Rey Juan Carlos - España
Univ Rey Juan Carlos - España |
| 30 | Novais, Paulo | Hombre |
Universidade do Minho - Portugal
Univ Minho - Portugal |
| 31 | Palacios-Alonso, Daniel | Hombre |
Universidad Rey Juan Carlos - España
Univ Rey Juan Carlos - España |
| 32 | Pantrigo, Juan J. | Hombre |
Universidad Rey Juan Carlos - España
Univ Rey Juan Carlos - España |
| 33 | Payne, Bryson R. | Hombre |
University of North Georgia - Estados Unidos
Univ North Georgia - Estados Unidos |
| 34 | de la Paz López, Félix | Hombre |
Universidad Nacional de Educación a Distancia - España
Univ Nacl Educ Distancia - España |
| 35 | Pinninghoff, María Angélica | Mujer |
Universidad de Concepción - Chile
|
| 35 | Angelica Pinninghoff, M. | Mujer |
Universidad de Concepción - Chile
|
| 36 | Rincón, Mariano | Hombre |
Universidad Nacional de Educación a Distancia - España
Univ Nacl Educ Distancia - España |
| 37 | Santos, J. | Hombre |
Universidade da Coruña - España
Univ A Coruna - España |
| 38 | Thurnhofer-Hemsi, Karl | Hombre |
Universidad de Málaga - España
Univ Malaga - España |
| 39 | Tsanas, Athanasios | Hombre |
The University of Edinburgh - Reino Unido
UNIV EDINBURGH - Reino Unido |
| 40 | Varela, Ramiro | Hombre |
Universidad de Oviedo - España
Univ Oviedo - España |
| 41 | Ferrández, Jose M. | Hombre |
Universidad Politécnica de Cartagena - España
Univ Politecn Cartagena - España |
| Fuente |
|---|
| National Natural Science Foundation of China |
| National Institutes of Health |
| Spanish Ministry of Science |
| Medical Research Council |
| Pfizer Inc. |
| Canadian Institutes of Health Research |
| Alzheimer's Association |
| Ministerio de Ciencia e Innovación |
| Royal Society |
| Bristol-Myers Squibb |
| University of California, San Diego |
| Engineering and Physical Sciences Research Council |
| British Council |
| Servier |
| Lundbeck |
| Eisai |
| Comunidad de Madrid |
| Michael J. Fox Foundation for Parkinson's Research |
| National Institute on Aging |
| Abbott Laboratories |
| Merck Co., Inc. |
| AbbVie |
| U.S. Department of Defense |
| Pfizer |
| Eli Lilly and Company |
| Genentech |
| Mauritius Research Council |
| University of Southern California |
| FPU Program |
| Abbott |
| Juan de la Cierva |
| Alzheimer’s Association |
| Merck & Co |
| Roche |
| GE Healthcare |
| Biogen |
| National Institute of Biomedical Imaging and Bioengineering |
| Euroimmun |
| H. Lundbeck A/S |
| Takeda Pharmaceutical Company |
| Bristol-Myers Squibb Company |
| Biogen Idec |
| Novartis Pharmaceuticals Corporation |
| Eisai Inc. |
| BioClinica, Inc. |
| Lumosity |
| Piramal Imaging |
| Neurotrack Technologies |
| Elan Pharmaceuticals, Inc. |
| IXICO Ltd. |
| CereSpir, Inc. |
| NeuroRx Research |
| Transition Therapeutics |
| Alzheimer's Drug Discovery Foundation |
| Janssen Alzheimer Immunotherapy Research & Development, LLC. |
| Fujirebio |
| Araclon Biotech |
| DOD ADNI |
| BioClinica |
| Johnson & Johnson Pharmaceutical Research & Development LLC. |
| Meso Scale Diagnostics, LLC. |
| Alzheimer's Disease Neuroimaging Initiative |
| Johnson and Johnson Pharmaceutical Research and Development |
| DoD Alzheimer's Disease Neuroimaging Initiative |
| F. Hoffman-La Roche Ltd. |
| Conselleria de Cultura, Educacion e Ordenacion Universitaria of Galicia |
| Autonomous Government of Andalusia (Spain) |
| DOD ADNI (Department of Defense) |
| F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc. |
| Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) |
| Fujirebio Europe |
| Janssen Alzheimer Immunotherapy Research AMP; Development, LLC. |
| Johnson AMP; Johnson Pharmaceutical Research AMP; Development LLC. |
| Janssen Alzheimer Immunotherapy Research And Development |
| Northern California Institute for Research and Education |
| Ordenaci?n Universitaria of Galicia |
| Agradecimiento |
|---|
| The work reported here has been partially funded by many public and private bodies. Spanish Ministry of Science, projects: TIN2017-85827-P, RTI2018-098913-B-I00, PSI2015-65848-R, PGC2018-098813-B-C31, PGC2018-098813-B-C32, RTI2018-101114-B-I, TIN2017-90135-R, RTI2018-098743-B-I00 and RTI2018-094645-B-I00; the FPU program (FPU15/06512, FPU17/04154) and Juan de la Cierva (FJCI-2017?33022). Autonomous Government of Andalusia (Spain) projects: UMA18-FEDERJA-084. Conseller?a de Cultura, Educaci?n e Ordenaci?n Universitaria of Galicia: ED431C2017/12, accreditation 2016?2019, ED431G/08, ED431C2018/29, Comunidad de Madrid, Y2018/EMT-5062 and grant ED431F2018/02. PPMI ? a public ? private partnership ? is funded by The Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbott, Biogen Idec, F. Hoffman-La Roche Ltd. GE Healthcare, Genentech and Pfizer Inc. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.;Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co. Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. |
| PPMI – a public – private partnership – is funded by The Michael J. Fox Foundation for Parkinson’s Research and funding partners, including Abbott, Biogen Idec, F. Hoffman-La Roche Ltd., GE Healthcare, Genentech and Pfizer Inc. |
| Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.;Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. |
| Prof. Yu-Dong Zhang received his BE in 2004, and MPhil in 2007, from Nanjing University of Aeronautics and Astronautics. He received the PhD degree from Southeast University in 2010. He worked as a postdoc from 2010 to 2012 with Columbia University, USA; and as an assistant research scientist from 2012 to 2013 with Research Foundation of Mental Hygiene (RFMH), USA. He served as a full professor from 2013 to 2017 with Nanjing Normal University. Now he serves as Professor with Department of Informatics, University of Leicester, UK. Prof. Zhang is the fellow of IET (FIET). He was included in “Most Cited Chinese researchers (Computer Science)” by Elsevier from 2014 to 2018. He was the 2019 recipient of “Highly Cited Researcher” by Web of Science. He has conducted many successful industrial projects and academic grants from NSFC, NIH, Royal Society, EPSRC, MRC, and British Council. |
| The work reported here has been partially funded by many public and private bodies. Spanish Ministry of Science, projects: TIN2017-85827-P, RTI2018-098913-B-I00, PSI2015-65848-R, PGC2018-098813-B-C31, PGC2018-098813-B-C32, RTI2018-101114-B-I, TIN2017-90135-R, RTI2018-098743-B-I00 and RTI2018-094645-B-I00; the FPU program (FPU15/06512, FPU17/04154) and Juan de la Cierva (FJCI-2017-33022). Autonomous Government of Andalusia (Spain) projects: UMA18-FEDERJA-084. Conselleria de Cultura, Educacion e Ordenacion Universitaria of Galicia: ED431C2017/12, accreditation 2016-2019, ED431G/08, ED431C2018/29, Comunidad de Madrid, Y2018/EMT-5062 and grant ED431F2018/02.r PPMI - a public - private partnership - is funded by The Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbott, Biogen Idec, F. Hoffman-La Roche Ltd., GE Healthcare, Genentech and Pfizer Inc.r Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.;Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. |